Enliven Therapeutics Business Summary

Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company that operates as a pre-revenue research and development entity focused on the discovery and commercialization of next-generation precision oncology small molecule inhibitors. The company’s business model is centered on advancing its proprietary pipeline through clinical trials to address unmet needs in cancer treatment, with primary segments divided by its lead therapeutic programs: ELVN-001, a highly selective BCR-ABL inhibitor for chronic myeloid leukemia (CML), and ELVN-002, a potent HER2 inhibitor targeting non-small cell lung cancer and other solid tumors. Enliven competes directly with other precision oncology firms such as Kymera Therapeutics, Cogent Biosciences, and Tempest Therapeutics. Within this landscape, Enliven positions itself as a specialized developer of "best-in-class" assets, leveraging differentiated chemistry to achieve superior selectivity and safety profiles compared to existing multi-kinase inhibitors. The company is led by Chief Executive Officer Rick Fair, who joined in late 2025 with over 25 years of oncology commercialization experience from Bellicum Pharmaceuticals and Roche/Genentech. The founding team includes Sam Kintz (Co-founder and current Head of Pipeline), Dr. Joe Lyssikatos (Co-founder and Chief Scientific Officer), and Dr. Anish Patel (Co-founder and Chief Operating Officer), all of whom bring extensive pedigrees from Array BioPharma and AbbVie. Other key executives include Chief Medical Officer Dr. Helen Collins and CFO Ben Hohl. Enliven’s strategic direction is supported by a high-profile Board of Directors chaired by Richard Heyman and recently bolstered by the addition of commercial veteran Scott Garland in January 2026. The company is backed by prominent institutional investors, including OrbiMed, 5AM Ventures, and Roche Venture Fund, maintaining a robust cash runway to support its transition into pivotal Phase 3 trials.